Related Experiment Video
Updated: Jul 20, 2026

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay
Published on: September 9, 2012
Effects of factor Xa and protein S on the individual activated protein C-mediated cleavages of coagulation factor Va
Eva A Norstrøm1, Sinh Tran, Mårten Steen
1Department of Laboratory Medicine, Clinical Chemistry, Lund University, the Wallenberg Laboratory, University Hospital, Malmö, SE-205 02 Malmö, Sweden.
Insights
Activated protein C inactivates factor Va (FVa) by cleaving it at specific sites. Factor Xa (FXa) inhibits cleavage at Arg-506, but Protein S counteracts this inhibition, revealing complex interactions in blood coagulation.
Area of Science:
- Biochemistry
- Hematology
- Molecular Biology
Background:
- Activated protein C (APC) is a key regulator of blood coagulation, primarily by inactivating activated factor V (FVa).
- APC cleaves FVa at multiple sites, with Arg-506 being the most kinetically favored, but this site is protected by factor Xa (FXa).
- The role of Protein S in modulating FXa's protection of FVa at Arg-506 is debated.
Purpose of the Study:
- To investigate the specific effects of FXa and Protein S on the individual cleavage sites of FVa.
- To elucidate the mechanism by which Protein S influences FXa's interaction with FVa at the Arg-506 cleavage site.
Main Methods:
- Utilized recombinant FVa variants (FVa:Q306/Q679 and FVa:Q506/Q679) to isolate effects on specific cleavage sites.
- Measured FVa inactivation rates over time in the presence of active site-blocked FXa (FXa-1.5-dansyl-Glu-Gly-Arg).
- Calculated apparent second-order rate constants to quantify inhibition and stimulation effects.
Main Results:
- FXa significantly inhibited FVa cleavage at Arg-506 (20-fold decrease, IC50 ~2 nM).
- FXa unexpectedly stimulated FVa cleavage at Arg-306.
- Protein S counteracted FXa's inhibition of Arg-506 cleavage and, with FXa, showed an additive stimulatory effect on Arg-306 cleavage.
Conclusions:
- FXa and Protein S interact with distinct sites on FVa, as Protein S does not inhibit FXa binding.
- Protein S enhances Arg-506 cleavage of FVa not bound to FXa, leading to FXa dissociation and apparent 'annihilation' of FXa's protective effect.
- These findings clarify the complex interplay of FXa and Protein S in regulating FVa inactivation by APC.
Abstract:
Activated protein C inhibits the procoagulant function of activated factor V (FVa) through proteolytic cleavages at Arg-306, Arg-506, and Arg-679. The cleavage at Arg-506 is kinetically favored but protected by factor Xa (FXa). Protein S has been suggested to annihilate the inhibitory effect of FXa, a proposal that has been challenged. To elucidate the effects of FXa and protein S on the individual cleavage sites of FVa, we used recombinant FVa:Q306/Q679 and FVa:Q506/Q679 variants, which can only be cleaved at Arg-506 and Arg-306, respectively. In the presence of active site blocked FXa (FXa-1.5-dansyl-Glu-Gly-Arg), the FVa inactivation was followed over time, and apparent second order rate constants were calculated. Consistent with results on record, we observed that FXa-1.5-dansyl-Glu-Gly-Arg decreased the Arg-506 cleavage by 20-fold, with a half-maximum inhibition of approximately 2 nM. Interestingly and in contrast to the inhibitory effect of FXa on the 506 cleavage, FXa stimulated the Arg-306 cleavage. Protein S counteracted the inhibition by FXa of the Arg-506 cleavage, whereas protein S and FXa yielded additive stimulatory effect of the cleavage at Arg-306. This suggests that FXa and protein S interact with distinct sites on FVa, which is consistent with the observed lack of inhibitory effect on FXa binding to FVa by protein S. We propose that the apparent annihilation of the FXa protection of the Arg-506 cleavage by protein S is due to an enhanced rate of Arg-506 cleavage of FVa not bound to FXa, resulting in depletion of free FVa and dissociation of FXa-FVa complexes.
Related Concept Videos
Extrinsic and Intrinsic Pathways of Hemostasis
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which forms a...
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Clot Retraction and Fibrinolysis
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Coagulation
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...
Coagulation

